01—Abstract
Summary
Summary of the 10-Q filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation's Form 10-Q for the quarter ended September 30, 2024 reports third-quarter total revenues of $748.9 milliona, up from $609.4 million, and nine-month revenues of $2.14 billion, up from $1.71 billion.
Net income was $309.1 millionb for the quarter versus $267.6 million a year earlier, and $893.8 million for the nine months versus $767.7 million. Diluted EPS was $6.39 for the quarter and $18.43 for the nine months. Growth was led by Tyvaso DPI, with total Tyvaso net product sales of $433.8 million for the quarter and $1,204.5 million for the nine months.
Quarterly operating expenses rose sharply, with selling, general, and administrative expense of $219.2 millionc including a $65.1 million litigation accrual related to the Sandoz litigation. Research and development expense was $103.5 million for the quarter. Share-based compensation was $117.0 million for the nine months, compared with $22.5 million a year earlier, largely reflecting STAP award remeasurement and higher RSU expense.
The company's balance sheet shows cash and cash equivalents of $1,553.9 milliond and marketable investments of $3,052.0 million combined, totaling $4,605.9 million. During the nine months, the company repurchased $1.0 billion of common stock under an accelerated share repurchase agreement and repaid $300.0 million on its credit line, leaving $400.0 million outstanding. The filing also describes ongoing litigation with Liquidia Technologies over Yutrepia, a pending FDA exclusivity dispute, and several lawsuits involving charitable donations and 340B program policies.
02—Key points
Key Highlights
- Total revenues were $748.9 million for the third quarter of 2024, up from $609.4 million, and $2,141.5 million for the nine months, up from $1,712.8 million.
- Tyvaso DPI net product sales were $274.6 million for the quarter, versus $205.1 million a year earlier, and total Tyvaso net product sales were $433.8 million.
- Net income was $309.1 million for the quarter and $893.8 million for the nine months; diluted EPS was $6.39 and $18.43, respectively.
- SG&A expense rose to $219.2 million for the quarter, including a $65.1 million litigation accrual related to the Sandoz lawsuit, which the company says could be higher or lower depending on the final judgment.
- The company repurchased $1.0 billion of common stock under an accelerated share repurchase agreement and repaid $300.0 million on its credit agreement, which now has $400.0 million outstanding.
- Cash, cash equivalents, and marketable investments totaled $4,605.9 million at September 30, 2024, compared with $4,903.9 million at December 31, 2023.
- The Federal Circuit affirmed the PTAB decision on the '901 patent, and the FDA granted Liquidia tentative approval for Yutrepia on August 16, 2024, with final approval barred until exclusivity expires in May 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, United Therapeutics kept $0.41.
- Revenue$748.9M100.0%
- Cost of revenue−$83.1M11.1%
- Gross profit$665.8M88.9%
- Operating costs−$322.7M43.1%
- Operating income$343.1M45.8%
- Interest, other & tax−$34.0M4.5%
- Net income$309.1M41.3%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 30, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $748.90M$609.40M | +22.9% |
| Cost of Revenue | $83.10M$70.10M | +18.5% |
| Gross Profit | $665.80M$539.30M | +23.5% |
| R&D Expenses | $103.50M$84.70M | +22.2% |
| SG&A Expenses | $219.20M$127.60M | +71.8% |
| Operating Expenses | $405.80M$282.40M | +43.7% |
| Operating Income | $343.10M$327.00M | +4.9% |
| Net Income | $309.10M$267.60M | +15.5% |
| EPS (Basic) | $6.93$5.71 | +21.4% |
| EPS (Diluted) | $6.39$5.38 | +18.8% |
| Shares Outstanding (Basic) | 44.60M46.90M | −4.9% |
| Shares Outstanding (Diluted) | 48.40M49.70M | −2.6% |
05—Questions
Frequently Asked Questions
What drove the increase in revenue?
The filing attributes growth mainly to Tyvaso DPI, whose quarterly net product sales rose 34% to $274.6 million, along with nebulized Tyvaso, Orenitram, and Unituxin. Growth reflected higher quantities sold, continued PH-ILD patient growth, and some price increases, including the effects of the Part D redesign under the Inflation Reduction Act.
Why did operating expenses increase so much in the quarter?
Total operating expenses were $405.8 million versus $282.4 million a year earlier. The largest drivers were a $65.1 million litigation accrual tied to the Sandoz matter, higher share-based compensation of $41.7 million versus $21.1 million, and higher general and administrative expense from headcount growth.
What is the status of the Sandoz litigation?
The court issued an opinion on September 6, 2024, without specifying damages. The parties submitted their positions on October 7, 2024, and are awaiting the court's decision. The company accrued $65.1 million in the third quarter and says any loss beyond that accrual is not expected to be material, though the final amount could be higher or lower.
What is the company's liquidity and debt position?
Cash and cash equivalents were $1,553.9 million and marketable investments totaled $3,052.0 million at September 30, 2024. The company repaid $300.0 million on its credit agreement during the nine months, leaving $400.0 million outstanding, which it classifies as current because it intends to repay that amount within one year.
What competitive threats does the filing highlight?
The filing identifies Liquidia's Yutrepia as a potential competitor to Tyvaso DPI and nebulized Tyvaso, with final FDA approval currently barred until exclusivity expires in May 2025. It also cites Merck's Winrevair, approved in March 2024, and potential generic competition, including Watson's nebulized Tyvaso generic beginning January 2026.
06—Continue